《European Journal Of Heart Failure》重点专注发布医学-心血管系统领域的新研究，旨在促进和传播该领域相关的新技术和新知识。鼓励该领域研究者详细地发表他们的高质量实验研究和理论结果。根据网友分享的投稿经验，平均审稿速度为 约1月 。该杂志创刊至今，在医学-心血管系统领域，影响力非凡，对来稿文章质量要求很高，稿件投稿过审难度很大，刊登文章的学术水平和编辑质量在同类杂志中均名列前茅。如果你想在该杂志上发表论文，你可以向编辑部提交文章，但文章必须具有重要意义并代表该领域专业的发展。我们欢迎广大同领域的研究者提交投稿。
| CiteScore | SJR | SNIP | CiteScore排名 | |||
|---|---|---|---|---|---|---|
| 27.3 | 5.919 | 3.208 | 学科类别 | 分区 | 排名 | 百分位 |
|
大类：大类：Medicine
小类：小类：CardiologyandCardiovascularMedicine
|
Q1 | 7/387 | 98% | |||
| 按JIF指标学科分区 | 收录子集 | 分区 | 排名 | 百分位 |
|---|---|---|---|---|
| 学科：CARDIAC & CARDIOVASCULAR SYSTEMS | SCIE | Q1 | 5 / 220 | 98% |
| 按JCI指标学科分区 | 收录子集 | 分区 | 排名 | 百分位 |
|---|---|---|---|---|
| 学科：CARDIAC & CARDIOVASCULAR SYSTEMS | SCIE | Q1 | 7 / 220 | 97.05% |
文章名称
引用次数
Clinical practice update on heart failure 2019: pharmacotherapy, procedures, devices and patient management. An expert consensus meeting report of the Heart Failure Association of the European Society of Cardiology
120
The use of diuretics in heart failure with congestion - a position statement from the Heart Failure Association of the European Society of Cardiology
94
Type 2 diabetes mellitus and heart failure: a position statement from the Heart Failure Association of the European Society of Cardiology
80
Advanced heart failure: a position statement of the Heart Failure Association of the European Society of Cardiology
76
A trial to evaluate the effect of the sodium-glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-HF)
55
Heart Failure Association of the European Society of Cardiology practical guidance on the use of natriuretic peptide concentrations
53
Heart failure with mid-range ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum
46
Evaluation of the effects of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality in patients with chronic heart failure and a preserved ejection fraction: rationale for and design of the EMPEROR-Preserved Trial
45
Sodium-glucose co-transporter 2 inhibition with empagliflozin improves cardiac function in non-diabetic rats with left ventricular dysfunction after myocardial infarction
44
Right heart dysfunction and failure in heart failure with preserved ejection fraction: mechanisms and management. Position statement on behalf of the Heart Failure Association of the European Society of Cardiology
43
国家/地区
发文量
TUSA
635
TItaly
563
TGERMANY (FED REP GER)
469
TEngland
412
TRussia
393
TSpain
386
TNetherlands
330
TPortugal
251
TFrance
246
TGreece
222
